Clinical impact of uncontrolled complement activity in Japanese non-transfused patients with paroxysmal nocturnal hemoglobinuria

)–Mean SE FACIT-Fatigue scores increased from 39.0 1.86 and 32.5 13.50 at baseline to 42.3 1.54 and 46.5 4.50 at 12 weeks for non-transfused patients and transfused patients, respectively •Eculizumab treatment resulted in changes of 5 and 23 points (> 3-point improvement is considered clinically meaningful) over 12 weeks in the FACIT-Fatigue scores for the 2 non-transfused patients, respectively• Treatment with eculizumab resulted in improvements in QoL, as measured by EORTC QLQ-C30, in patients with and without a transfusion history (